ANI Pharmaceuticals Jefferies Global Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Hi, good morning. Welcome to the Jefferies Healthcare Conference in London. My name is Dennis Ding, biotech and spec pharma analyst here at Jefferies. I have the wonderful pleasure of having ANI Pharmaceuticals here. Nikhil and Stephen, welcome. Nikhil, I believe you have some slides that you want to go through, then we can kind of go into Q&A.
Sure. Good morning, everybody, and thank you for joining us at the Jefferies Conference. Thank you, Dennis and the Jefferies team, for having us here. Here's our standard forward-looking statements. ANI is a high-growth biopharmaceutical organization that's leading our transformation, accelerating our transformation into a leading rare disease company. Our rare disease business accounts for more than 50% of our sales with our lead asset, Purified Cortrophin Gel, which is a strong multi-year growth opportunity. We're going to do about $480 million to $500 million in sales with that asset, but it has continuous growth available with it. Then we've recently made an offer to acquire Egetis Therapeutics with a lead asset called Emcitate that I will tell you about, to expand the scope and scale of our rare disease business.
At ANI, we have what we believe is a virtuous cycle of growth, where we take EBITDA and cash flows from our high-performing generics business and reinvest it into our rare disease business to accelerate our transformation into rare disease. When you think of ANI in numbers, we'll cross about $1.1 billion in sales this year, and our EBITDA, adjusted non-GAAP EBITDA, is at $290 million-$300 million, showing $295 million. ANI has a strong improvement track record of growth, both on the top line as well as on the bottom line. You can see that over the past five years, we've had about 37% growth compounded on the top line, then our profitability has increased substantially with a 51% growth on the bottom line. Rare disease has been the primary driver of our growth. It's a business we launched in 2022 with our lead asset, Cortrophin Gel.
Year one of launch, we did $42 million of sales. That asset, our guidance for this year is 10x that, more than 10x that, at about $480 million-$500 million. On a combined basis, the rare disease business will account for $560 million-$585 million, where our second asset, ILUVIEN, will do $80 million-$85 million in sales. In the third quarter, Cortrophin delivered $138.7 million in sales. Cortrophin is an asset that is used across multiple indications. Our existing specialties are neurology, nephrology, rheumatology, ophthalmology, and pulmonology. Across these five indications, we continue to have growth. These are the indications we launched with, or three of them we launched with, then we added sales later on with the other two, ophthalmology and pulmonology.
We continue to see very strong demand across our existing specialties, and that demand momentum has continued into October, where we saw the highest number of new cases initiated in October, as well as from the gout expansion. For gout, we expanded our sales force by about 50% to detail into primary care and podiatrists, and that expansion has gone very well, and we've seen very strong demand that we will talk about soon. ILUVIEN had a very strong growth quarter too, with $22.3 million. Importantly, we announced phase IV study results, the SYNCHRONICITY data, that we believe will help prescribers think about ILUVIEN and the treatment of chronic NIU-PS. When you look at a total company basis, our guidance for the year is $1.085 billion-$1.125 billion, which is a 23%-27% growth.
For Cortrophin, our guidance is $480 million-$500 million, which is 38%-44% growth. ILUVIEN is $80 million-$85 million, which is 7%-14% growth. The adjusted non-GAAP EBITDA is at 26%-31% of growth, which is $290 million-$300 million. Importantly, our balance sheet is very strong. We've generated more than $200 million of cash in the last nine months from operations, and we're sitting at $421 million as of September 30th, and 0.7 turns of net leverage as of September 30th. Lastly, before we go to Q&A, we made an offer to acquire Egetis Therapeutics, a Sweden-based rare disease company. Their lead asset, Emcitate, is the only approved therapeutic for peripheral thyrotoxicosis associated with MCT8 deficiency, which is an ultra-rare X-linked, which means it impacts only males, disease. It's a debilitating condition. Most importantly, it allows us to bring this therapeutic to patients.
It's the only approved therapeutic for this disease, and it allows us to bring this therapeutic and continue on our purpose of serving patients, improving lives, because it addresses a patient population that has no other alternative, and it's really a very debilitating life condition that has morbidity associated with it too. We are grateful for the opportunity to bring this therapeutic to patients, not just in the U.S., but also globally. It leverages our rare disease infrastructure expertise, and adds and expands the scope and scale of our rare disease business. It also adds a pipeline for us, because the same drug, Emcitate, is being considered for development for the treatment of RTH-beta, which the Egetis team had been working on. It also brings that clinical development capability to ANI.
It's a durable, high-growth asset. It has patent that goes until 2045. It has ODE exclusivity until 2033. What it does in aggregate, it diversifies our revenue base from rare disease and improves the long-term growth and profitability. Heading towards the end of this decade, we'll have substantial majority of our sales and improved profitability across our rare disease business. I think I've covered most of this, so maybe I'll just turn it over to Dennis for Q&A.
Yeah, sure. Thanks, Nikhil, for those comments. Maybe we can just start off with the acquisition. Talk a little bit about the rationale behind it. Why now? Why today? And how do you think about the opportunity in the U.S.?
Yeah. For those less familiar, ANI does not, in rare disease, as we are looking to expand our scope and scale of our rare disease business, we do not have our own R&D, so we look for external assets. And when we were looking at what kind of assets to add, we wanted to either leverage our front end, which is our sales force, that, as I was mentioning earlier, goes into multiple indications, rheumatology, nephrology, neurology, pulmonology, and ophthalmology, or the backbone of the rare disease business, which is patient support, medical affairs, specialty pharmacy distribution, market access. What the Egetis Therapeutics acquisition does is it leverages the backbone, our rare disease infrastructure and backbone, and allows us to bring this important therapeutic, first in class, to patients in need. It has all of the attributes that we were looking for as we have been scanning assets.
It is a first-in-class therapeutic. It is FDA approved. That was important. We did not want to take clinical risk or regulatory risk at the time. It is an asset with peak sales $300 million plus, which is in the range of what we were looking for. It allows us to use our balance sheet, but does not stress our balance sheet beyond. Even after close of this deal, we will be at 2.7 turns of net leverage with a path to delevering. So, I think it plays an important role in expanding the scope and scale of our rare disease business. Also, last but not least, it is also a profitable, improves the profitability profile for our rare disease business too.
Sure. In the U.S., because this is an ultra-rare- Yeah condition, can you just remind us how many patients are identified?
This is approved, and once you guys get the business integrated, you are going to go out there and prioritize those patients.
Sure. The Egetis team, again, a lot of respect for them and what they have. It is really impressive what this company has achieved and the team has achieved globally in terms of getting the drug approved, but also the progress that they made. They have got it approved both in Europe and the U.S. In Europe, they have launched in Germany, and they have doubled the number of patients since last year of the number of patients that are treated with MCT8, which is tremendous. In the U.S., they have identified more than 100 patients that are genetically validated. So they have identified and genetically validated more than 100 patients. Of those 100 plus patients, 60 are already on the expanded access program.
Since the approval on September 28th, their first focus has been to get these patients shifted from EAP onto the approved drug and through the commercial approval process, as well as the remaining 40 plus patients, because 100 minus 60 plus patients, also onto therapy. So that has been their initial focus. They have put in place a number of different elements that are needed for a successful launch, which is they have got partnerships with AnovoRx on the specialty pharmacy front, which is much needed for an ultra-rare indication like MCT8 deficiency. They have also partnered with diagnostics organizations for the genetic testing as well as for the T3 level testing using LC-MS. They have also built a very strong relationship with the caregiver and the foundation associated with MCT8 deficiency.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
3 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
